New Game Mode. 👀 We just added Rapid Review, a brand new game mode to Rounds. This game mode lets you compete with friends with 1 hint and 1 minute to get as many diagnoses right as you can.

Rifampin Adverse Effects

Infectious Disease

Illness script · Infectious Disease

Rifampin Adverse Effects

Broad-spectrum antimycobacterial drug notable for orange body-fluid discoloration, potent CYP450 induction, and hepatotoxicity.

This illness script for Rifampin Adverse Effects covers predisposing factors, classic presentation, mechanism, workup, management, and the clinical pivots that separate it from look-alikes—written for USMLE Step 1 and clerkship reasoning.

Updated Nov 19, 2026All scripts

01

Predisposing factors

  • Used in TB, leprosy, and meningococcal/H. influenzae prophylaxis
  • Patients on polypharmacy (warfarin, OCPs, antiretrovirals, methadone) at high interaction risk
  • Intermittent/high-dose regimens increase flu-like syndrome and thrombocytopenia risk
  • Pre-existing liver disease increases hepatotoxicity risk
  • Combined use with isoniazid and pyrazinamide is synergistically hepatotoxic

02

Presentation

  • Orange-red discoloration of urine, tears, sweat, saliva — pathognomonic and benign
  • Flu-like syndrome: fever, chills, myalgias — especially with intermittent dosing
  • Jaundice, nausea, elevated LFTs — hepatotoxicity (can be severe in combo therapy)
  • Purpura, bleeding — immune thrombocytopenia
  • Drug interaction effects: OCP failure (unintended pregnancy), subtherapeutic warfarin, ART failure

03

Pathophysiology

  • Potent inducer of CYP3A4, 2C9, 2C19 — accelerates metabolism of co-administered drugs
  • Rifampin metabolites excreted in bile, urine, tears → orange-red pigmentation of all body fluids
  • Hepatocellular toxicity via reactive metabolite formation, especially in combination regimens
  • Intermittent dosing generates anti-rifampin antibodies → immune-mediated thrombocytopenia and flu-like reactions

04

Diagnostics

  • Baseline LFTs, CBC, and bilirubin before initiating therapy
  • Monitor LFTs monthly — hold if >3–5× ULN with symptoms
  • Check drug interactions for ALL co-medications via CYP3A4 induction
  • Soft contact lens staining by tears is irreversible — warn patients preemptively
  • No specific rifampin drug level monitoring routinely used

05

Management

  • Orange discoloration: reassurance only — no dose change needed
  • Hepatotoxicity: hold rifampin if symptomatic or LFTs >5× ULN; switch regimen
  • Flu-like syndrome: convert to daily (not intermittent) dosing
  • Thrombocytopenia: permanently discontinue rifampin
  • Drug interactions: switch OCPs to barrier method; increase warfarin monitoring; adjust ART regimen

06

Clinical pivots

How to separate this script from the look-alikes that show up on exams and on the wards.

  • Isoniazid (INH) toxicity

    INH causes peripheral neuropathy (B6 deficiency) and drug-induced lupus; rifampin causes orange discoloration and CYP induction — not INH.

  • Pyrazinamide (PZA) toxicity

    PZA causes hyperuricemia/gout and is the dominant hepatotoxin in RIPE; rifampin's signature toxicity is CYP induction and orange discoloration.

  • Ethambutol toxicity

    Ethambutol causes optic neuritis with red-green color blindness; rifampin does not affect vision.

  • Viral hepatitis

    Drug-induced hepatitis from rifampin has clear temporal relation to drug initiation and resolves with discontinuation, unlike acute viral hepatitis.

View full library

Educational use only. This illness script is a study framework, not medical advice. Confirm decisions with current guidelines and your clinical supervisors.